# Akamis Bio

> Akamis Bio is a clinical-stage oncology company building intravenously delivered, tumor-targeted gene therapies on its Tumor-Specific Immuno-Gene (T-SIGn) platform. Using a replication-competent, directed-evolution-engineered group B adenovirus that selectively infects epithelial-derived solid tumors, Akamis turns cancer cells into local 'drug factories' that express immune-modulating payloads inside the tumor while sparing healthy tissue. Headquartered in Cambridge, Massachusetts (with UK roots as the former PsiOxus Therapeutics), its lead program NG-350A delivers a CD40 agonist antibody directly to primary and metastatic tumors.

- **Founded:** 2010
- **Headquarters:** Cambridge, Massachusetts, United States
- **Founders:** John Beadle (Co-founder (founding CEO, PsiOxus)), Kerry Fisher (Co-founder, Chief Scientific Officer), Andrew Coats (Co-founder)
- **Team size:** ~36 employees
- **Products:** T-SIGn platform, NG-350A, FORTRESS trial
- **Notable:** Rebranded from PsiOxus Therapeutics to Akamis Bio with a US relaunch and new financing., Over 240 patients dosed across T-SIGn clinical studies., Demonstrated initial proof of mechanism for NG-350A as an IV-dosed gene therapy delivering a CD40 agonist payload, published in peer-reviewed literature.

## Products & services

- **T-SIGn platform** — Tumor-Specific Immuno-Gene therapy platform built on a replication-competent, chimeric group B adenovirus optimized via directed evolution to selectively infect epithelial-derived solid tumors and drive intratumoral expression of multiple transgene payloads.
- **NG-350A** — Lead clinical candidate: an intravenously delivered, transgene-armed tumor gene therapy that drives intratumoral expression of a CD40 agonist monoclonal antibody in primary and metastatic epithelial-derived solid tumors.
- **FORTRESS trial** — Phase 1b clinical proof-of-concept study evaluating NG-350A in patients with locally advanced rectal cancer (LARC).

## Achievements

- Rebranded from PsiOxus Therapeutics to Akamis Bio with a US relaunch and new financing.
- Over 240 patients dosed across T-SIGn clinical studies.
- Demonstrated initial proof of mechanism for NG-350A as an IV-dosed gene therapy delivering a CD40 agonist payload, published in peer-reviewed literature.
- Closed $60M Series A Prime led by Sedgwick Yard (Dec 2024) and signed Greater China licensing deal with Xuanzhu Biopharma.
- Established T-SIGn platform collaborations with BMS, Merck, and the Parker Institute for Cancer Immunotherapy.

## Latest updates

- **2024-12** — Announced $60 million in funding linked to a Series A Prime financing (led by Sedgwick Yard) and a strategic licensing partnership granting Xuanzhu Biopharma Greater China rights to NG-350A.
- **2024-12** — Added Sedgwick Yard managing directors Richard Shen and Adrian Chan to its Board of Directors.
- **2024** — Enrolled first patient in the Phase 1b FORTRESS trial of NG-350A in locally advanced rectal cancer.

## Links

- Website: https://www.akamisbio.com
- LinkedIn: https://www.linkedin.com/company/akamisbio
- Twitter/X: https://twitter.com/AkamisBio

---

Profile page: https://yespress.io/akamis-bio
Published by YesPress — https://yespress.io
Last updated: 2026-06-07